|
|
|
|
|
30.05.25 - 13:48
|
US FDA approves Alcon′s Tryptyr ophthalmic solution for Dry Eye Disease (PBR)
|
|
|
Previously known as AR-15512, Tryptyr is a transient receptor potential melastatin 8 (TRPM8) receptor agonist that stimulates corneal sensory nerves to increase production of natural tears rapidly. It
The post US FDA approves Alcon's Tryptyr ophthalmic solution for Dry Eye Disease appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.05.25 - 22:36
|
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS (Business Wire)
|
|
|
First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024
First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73
Generated $384 million cash from operations and $278 million free cash flow3
Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025
Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025
Ad Hoc Announcement Pursuant to Art. 53 LR
GENEVA--(BUSINESS WIRE)--Regulatory News:
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31, 2025. For the first quarter of 2025, sales were $2.5 billion, flat on a reported basis and up 3% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.70 and core diluted earnings per share2 of $0.73 in the fir...
|
|
|
|
|
|
|
|
|
06.05.25 - 22:36
|
Alcon Announces Results of 2025 Annual General Meeting (Business Wire)
|
|
|
Shareholders approve all agenda items presented
Deborah Di Sanzo elected as new member of the Board
2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes
GENEVA--(BUSINESS WIRE)--Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting (“AGM”).
A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM.
Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood for re-election, namely Lynn Bleil, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel and Dieter Spälti, for a term of office of one year. Shareholders also elected Deborah Di Sanzo to the Board, effective as of September 1, 2025.
In addition, s...
|
|
|
01.05.25 - 21:21
|
XETR: NEW INSTRUMENT AVAILABLE - 02.05.2025 - CH0432492467 (XETRA)
|
|
|
Das Instrument 2U3 CH0432492467 ALCON AG NAM. SF -,04 EQUITY hat seinen ersten Handelstag am 02.05.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG SWI0, SettlCurr EUR, CCP Y
The instrument 2U3 CH0432492467 ALCON AG NAM. SF -,04 EQUITY has its first trading date on 02.05.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG SWI0, SettlCurr EUR, CCP Y...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
